Clinical Trial Update: A Study of Anagrelide and Hydroxyurea in High-Risk Essential Thrombocythemia Patients [Phase 4]

View source ↗

Summary

Phase 4 trial update for anagrelide and hydroxyurea in high-risk essential thrombocythemia completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Thrombocythemia Hemorrhagic

Drugs mentioned

• ANAGRELIDE (Anagrelide)
• HYDROXYUREA (Hydroxyurea)

Snippet

Sponsor: Shire | Conditions: Thrombocythemia, Hemorrhagic | Phase 4 | Status: COMPLETED | Results posted: 2018-01-24